PROCEPT BioRobotics Corporation PRCT R2K
Healthcare · Medical Devices · United States
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
READ MORE ›$26.33
-54.60% 1Y
Market & Price
Market Cap
$1.50B
Current Price
$26.33
High / Low (52W)
$65.05 / $21.71
Beta
0.83
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$6.11
Price to Book
4.31
P/S
4.65
EV/EBITDA
-13.00
Dividend Yield
-
Profitability & Returns
ROCE
-20.75%
ROE
-27.82%
ROA
-13.54%
Profit Margin
-31.82%
Op Margin
-39.22%
EPS (Latest Qtr)
$-0.56
EPS (TTM)
$-1.83
Balance Sheet & Liquidity
Debt/Equity
0.22
Quick Ratio
5.38
Current Ratio
6.73
Debt
$78.00M
Total Assets
$508.08M
Current Assets
$450.38M
Working Capital
$384.58M
Ownership
Promoter Holding
3.13%
Chg in Prom Hold
-
FII / Inst Holding
102.55%
Chg in FII Hold
-0.01%
Financial Snapshot
Enterprise Value
$1.33B
Total Revenue (TTM)
$322.02M
EBITDA
$-102.38M
Free Cash Flow
$-43.18M
Operating Cash Flow
$-70.13M
Shares Outstanding
56.92M
Gross Margin
63.97%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
60.14%
Profit 5Y
-3.22%
Revenue (YoY)
20.20%
Earnings (YoY)
-
PROS
- Compounding revenue at 60.1% over 5 years.
CONS
- Earnings shrank at -3.2% CAGR over 5 years.
- Trading 59.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PRCT PROCEPT BioRobotics Corporation R2K | 26.33 | - | $1.50B | - | -20.75% | -27.82% | 60.14% | -3.22% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 2.11M | 7.19M | 8.48M | 8.67M | 14.20M | 16.69M | 20.35M | 24.40M | 33.10M | 35.10M | 44.54M | 53.35M | 58.37M | 69.16M | 79.18M | 83.33M | 76.38M | 83.13M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 25.00M | 27.44M | 29.32M | 30.07M | 29.18M |
| Gross Profit | - | - | -31.00K | 3.53M | 3.58M | 4.24M | 7.69M | 8.49M | 10.23M | 12.49M | 18.43M | 18.87M | 25.03M | 31.48M | 36.91M | 44.16M | 51.75M | 54.01M | 46.31M | 53.95M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 71.60M | 73.94M | 77.20M | 77.35M | 86.55M |
| Operating Income | - | - | -10.98M | -11.34M | -13.19M | -12.80M | -15.70M | -17.88M | -22.11M | -28.38M | -25.62M | -25.61M | -27.65M | -26.83M | -22.43M | -27.44M | -22.19M | -23.19M | -31.04M | -32.61M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -22.43M | -17.09M | -18.87M | -27.05M | -29.13M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 877.00K | 895.00K | 919.00K | 894.00K | 818.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -24.78M | -19.58M | -21.41M | -29.66M | -31.68M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -47.00K | - | - | - | -43.00K |
| Net Income | -13.13M | -12.61M | -12.01M | -12.82M | -14.58M | -14.10M | -17.18M | -19.18M | -22.61M | -28.48M | -25.29M | -24.62M | -25.96M | -25.63M | -20.97M | -24.74M | -19.58M | -21.41M | -29.84M | -31.64M |
| Diluted EPS | - | - | -2.77 | -2.65 | -2.60 | -1.22 | -0.39 | -0.43 | -0.51 | -0.63 | -0.56 | -0.51 | -0.51 | -0.50 | -0.40 | -0.45 | -0.35 | -0.38 | -0.53 | -0.56 |
| R&D Expense | - | - | 3.89M | 4.52M | 4.48M | 4.92M | 5.01M | 6.71M | 7.58M | 10.74M | 11.61M | 11.60M | 13.08M | 17.50M | 16.65M | 16.40M | 17.63M | 18.19M | - | 21.46M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 7.72M | - | 75.01M | 136.19M | 224.50M | 308.05M |
| Cost of Revenue | - | - | 37.93M | 65.14M | 87.40M | 111.83M |
| Gross Profit | -1.25M | - | 37.09M | 71.05M | 137.10M | 196.23M |
| Operating Expenses | - | - | 117.81M | 180.22M | 233.71M | 300.08M |
| Operating Income | -47.80M | - | -80.72M | -109.17M | -96.61M | -103.86M |
| EBITDA | - | - | -79.13M | -98.02M | -81.63M | -85.41M |
| Interest Expense | - | - | 5.18M | 4.00M | 4.18M | 3.59M |
| Pretax Income | - | - | -87.15M | -105.82M | -91.05M | -95.38M |
| Tax Provision | - | - | - | 80.00K | 368.00K | 190.00K |
| Net Income | -53.02M | - | -87.15M | -105.90M | -91.41M | -95.57M |
| Diluted EPS | -14.47 | - | -1.96 | -2.24 | -1.75 | -1.72 |
| R&D Expense | 16.27M | 18.99M | 28.98M | 48.45M | 62.30M | 71.28M |
Compounded Sales Growth
| 5 Years: | 60.14% |
| 1 Year: | 20.20% |
Compounded Profit Growth
| 5 Years: | -3.22% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -54.60% |
| 6 Months: | -18.41% |
| 3 Months: | +16.04% |
| 1 Month: | +21.28% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 125.97M | - | 309.33M | 404.72M | 534.02M | 508.08M |
| Current Assets | - | - | - | 272.63M | 350.57M | 481.84M | 450.38M |
| Cash & Equivalents | - | 100.13M | - | 221.86M | 257.22M | 333.73M | 286.50M |
| Inventory | - | - | - | 28.54M | 39.76M | 56.17M | 70.69M |
| Receivables | - | - | - | 15.27M | 48.38M | 83.50M | 83.53M |
| Total Liabilities | - | 65.01M | - | 112.26M | 123.97M | 131.80M | 142.21M |
| Current Liabilities | - | 14.53M | - | 35.29M | 45.93M | 53.13M | 65.80M |
| Long Term Debt | - | 44.41M | - | 51.21M | 51.34M | 51.47M | 51.62M |
| Total Debt | - | - | - | 77.32M | 79.20M | 80.25M | 78.48M |
| Total Equity | -143.84M | -182.89M | - | 197.07M | 280.75M | 402.22M | 365.87M |
| Shares Outstanding | - | - | - | 44.83M | 50.77M | 54.72M | 56.32M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -48.34M | - | -80.38M | -108.00M | -99.21M | -48.98M |
| Investing Cash Flow | -233.00K | - | -2.65M | -25.21M | -4.41M | -9.36M |
| Financing Cash Flow | 106.77M | - | 3.61M | 167.79M | 180.12M | 11.19M |
| Capital Expenditure | -233.00K | - | -2.65M | -25.21M | -4.41M | -9.36M |
| Free Cash Flow | -48.58M | - | -83.03M | -133.21M | -103.62M | -58.34M |
| Net Change in Cash | - | - | -79.42M | 34.59M | 76.50M | -47.15M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | -16.3% | - | 49.4% | 52.2% | 61.1% | 63.7% |
| Operating Margin % | -619.4% | - | -107.6% | -80.2% | -43.0% | -33.7% |
| Net Margin % | -687.0% | - | -116.2% | -77.8% | -40.7% | -31.0% |
| ROE % | 29.0% | - | -44.2% | -37.7% | -22.7% | -26.1% |
| ROCE % | -42.9% | - | -29.5% | -30.4% | -20.1% | -23.5% |
Shareholding Pattern
Insiders
3.13%
Institutions
102.55%
Public Float
105.86%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.66% | 4.36M | $114.85M |
| 2 | T. Rowe Price Investment Management, Inc. | 5.75% | 3.27M | $86.20M |
| 3 | BNP Paribas Asset Management Holding S.A. | 5.43% | 3.09M | $81.34M |
| 4 | Vanguard Portfolio Management LLC | 4.25% | 2.42M | $63.75M |
| 5 | Vanguard Capital Management LLC | 4.21% | 2.40M | $63.17M |
| 6 | Chicago Capital, LLC | 3.80% | 2.16M | $56.89M |
| 7 | Prosight Management, Lp | 3.42% | 1.95M | $51.21M |
| 8 | Mackenzie Financial Corporation | 3.02% | 1.72M | $45.31M |
| 9 | State Street Corporation | 2.69% | 1.53M | $40.28M |
| 10 | FMR, LLC | 2.57% | 1.46M | $38.49M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PRCT
No recent headlines available.